Prophylactic IABP in High-risk Patients Undergoing CABG
Primary Purpose
Myocardial Infarction, Coronary Artery Disease
Status
Withdrawn
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Preoperative IABC
Sponsored by
About this trial
This is an interventional treatment trial for Myocardial Infarction focused on measuring IABP, IABC, coronary artery disease, prophylactic, cardiac assist
Eligibility Criteria
Key inclusion criteria:
Hemodynamically stable high-risk patients before CABG, defined by the following criteria:
- Age >18 years
- Isolated CABG planned
- Informed consent in trial participation given
- Any left ventricular functional impairment (regional wall motion abnormality or global LVEF<55%) assessed via ventriculography or transthoracic or transeophageal echocardiography
- Elevated cardiac biomarkers (CK-MB > 6% of total-CK, Troponin I > 3-fold of specific test reference) or myocardial infarction (NSTEMI or STEMI) within the last 4 days.
Key exclusion criteria:
- Contraindications for IABP
- Cardiogenic shock
- Shock of any other cause
- Critical preoperative state according to EuroSCORE II-criteria
- Cardiac surgical procedure other than CABG planned
- Severe comorbidity with life expectancy < 6 months
- Incapability of giving informed consent
Sites / Locations
- Department of Adult and Pediatric Cardiovascular Surgery
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
IABP group
Control group
Arm Description
Preoperative IABP insertion
Preoperative conservative treatment
Outcomes
Primary Outcome Measures
30-day all-cause mortality post CABG [%]
Secondary Outcome Measures
Survival at 3, 6, 12 months [%]
Duration of ICU stay [h]
Dependence on medical inotropic support
IABP-associated complications
IABP-associated complications occur most often during IABP-support. However, after weaning from IABP, patients can still have bleeding complications or thrombembolic complications. Therefore, IABP-associated complications are monitored during the whole hospital stay
Full Information
NCT ID
NCT01950130
First Posted
September 18, 2013
Last Updated
November 12, 2021
Sponsor
University of Giessen
1. Study Identification
Unique Protocol Identification Number
NCT01950130
Brief Title
Prophylactic IABP in High-risk Patients Undergoing CABG
Official Title
Prophylactic Preoperative Inatraaortic Balloon Pump (IABP) in High-risk Patients Undergoing Coronary Artery Bypass Surgery (CABG)
Study Type
Interventional
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Withdrawn
Why Stopped
No funding
Study Start Date
June 2015 (undefined)
Primary Completion Date
February 2017 (Anticipated)
Study Completion Date
February 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Giessen
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Due to advances and increased practice of interventional therapy for coronary artery disease, the rate of high-risk patients with severe coronary disease and reduced left ventricular function among patients undergoing coronary artery bypass grafting surgery (CABG) is increasing. The perioperative mortality in these patients is ≥ 5%. The perioperative and operative management for these patients has to be optimized in order to reduce their perioperative morbidity and mortality. One of the central aspects is perioperative maintenance of hemodynamic stability. The use of prophylactic IABP is a partly established, but not sufficiently evidence-based measure to reduce ventricular afterload and improve coronary perfusion pre-, intra- and postoperatively. Yet, it is an invasive procedure with potential complications. The planned trial should give an explicit answer, whether preoperative prophylactic IABP decreases 30-day all-cause mortality (primary endpoint) and long-term mortality (3, 6, 12 months; secondary endpoints) compared to preoperative conservative treatment in high-risk patients undergoing CABG.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Infarction, Coronary Artery Disease
Keywords
IABP, IABC, coronary artery disease, prophylactic, cardiac assist
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
IABP group
Arm Type
Experimental
Arm Description
Preoperative IABP insertion
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Preoperative conservative treatment
Intervention Type
Procedure
Intervention Name(s)
Preoperative IABC
Intervention Description
IABP-Insertion upon inclusion into the trial and admission to the ICU
Primary Outcome Measure Information:
Title
30-day all-cause mortality post CABG [%]
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Survival at 3, 6, 12 months [%]
Time Frame
3, 6 and 12 months
Title
Duration of ICU stay [h]
Time Frame
48 hours (average)
Title
Dependence on medical inotropic support
Time Frame
48 hours (average)
Title
IABP-associated complications
Description
IABP-associated complications occur most often during IABP-support. However, after weaning from IABP, patients can still have bleeding complications or thrombembolic complications. Therefore, IABP-associated complications are monitored during the whole hospital stay
Time Frame
8 days (average)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key inclusion criteria:
Hemodynamically stable high-risk patients before CABG, defined by the following criteria:
Age >18 years
Isolated CABG planned
Informed consent in trial participation given
Any left ventricular functional impairment (regional wall motion abnormality or global LVEF<55%) assessed via ventriculography or transthoracic or transeophageal echocardiography
Elevated cardiac biomarkers (CK-MB > 6% of total-CK, Troponin I > 3-fold of specific test reference) or myocardial infarction (NSTEMI or STEMI) within the last 4 days.
Key exclusion criteria:
Contraindications for IABP
Cardiogenic shock
Shock of any other cause
Critical preoperative state according to EuroSCORE II-criteria
Cardiac surgical procedure other than CABG planned
Severe comorbidity with life expectancy < 6 months
Incapability of giving informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philippe Grieshaber, MD
Organizational Affiliation
Giessen University
Official's Role
Study Director
Facility Information:
Facility Name
Department of Adult and Pediatric Cardiovascular Surgery
City
Giessen
ZIP/Postal Code
35392
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Prophylactic IABP in High-risk Patients Undergoing CABG
We'll reach out to this number within 24 hrs